Google
RNAC — CARTESIAN THERAPEUTICS INC. (Healthcare >> Biotechnology)
RNAC FAQ
What is RNAC's P/E ratio?
CARTESIAN THERAPEUTICS INC. (RNAC) currently trades at a P/E ratio of 15.79.
What is RNAC's ROE?
CARTESIAN THERAPEUTICS INC. reports a Return on Equity (ROE) of 102.47%.
What is RNAC's dividend yield?
CARTESIAN THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is RNAC's Deepscope Quality Score?
Deepscope rates RNAC's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RNAC?
Deepscope's AI Timing Score for RNAC is 96 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RNAC belong to?
CARTESIAN THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 9.51
Price
1.45
(17.99%)
Day Change
|
|
|---|
RNAC, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.51 |
| PBV / Sector |
-1.69 / 4.91
|
| Earning Per Share | -5.76 |
| PE / Sector |
15.79 / 18.34
|
| PEG or PE/Growth / Sector |
-0.08 / 0.61
|
| Average 1M Daily Value |
2.93 M
GREAT
|
| Average 1W Daily Value |
8.24 M
|
| Timing Factors |
|
85% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:53 |
| Symbol | RNAC |
| Name | CARTESIAN THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 29.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 250.77 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7495 New Horizon Way, Frederick, MD, United States, 21703
Phone: 301 348 8698
Website: https://www.cartesiantherapeutics.com
Employees: 75
Sector: Healthcare >> Biotechnology
Description: Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
